Evidence map›Paper›PMID 36702740›Full record

ArticleJapanese journal of clinical oncology2023

Patient-reported outcome and quality of life research policy: Japan Clinical Oncology Group (JCOG) policy.

Hiroto Ishiki, Yuichiro Kikawa, Mitsumi Terada, Junki Mizusawa, Michitaka Honda, Tsuguo Iwatani, Tomonori Mizutani, Keita Mori, Naoki Nakamura, Tempei Miyaji and 6 more

Abstract read
In one paragraph

Article in Japanese journal of clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Longitudinal assessment of quality-of-life after gastrectomy for gastric cancer: a prospective study.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Hiroto IshikiDepartment of Palliative Medicine, National Cancer Center Hospital, Tokyo, Japan.ORCID 0000-0002-0800-2161
Yuichiro KikawaDepartment of Breast Surgery, Kansai Medical University, Osaka, Japan.ORCID 0000-0002-3852-5991
Mitsumi TeradaDepartment of International Clinical Development, National Cancer Center Hospital, Tokyo, Japan.
Junki MizusawaJapan Clinical Oncology Group (JCOG) Data Center, National Cancer Center Hospital, Tokyo, Japan.
Michitaka HondaDepartment of Minimally Invasive Surgical and Medical Oncology, Fukushima Medical University, Fukushima, Japan.
Tsuguo IwataniDepartments of Breast and Endocrine Surgery, Okayama University Hospital, Okayama, Japan.
Tomonori MizutaniDepartment of Medical Oncology, Kyorin University Faculty of Medicine, Tokyo, Japan.ORCID 0000-0002-9345-1526
Keita MoriDepartment of Biostatistics, Clinical Research Center, Shizuoka Cancer Center, Shizuoka, Japan.
Naoki NakamuraDepartment of Radiation Oncology, St. Marianna University School of Medicine, Kawasaki, Japan.
Tempei MiyajiDivision of Supportive Care, Survivorship and Translational Research, Institute for Cancer Control, National Cancer Center, Tokyo, Japan.
Takuhiro YamaguchiDivision of Biostatistics, Tohoku University Graduate School of Medicine, Sendai, Japan.
Masahiko AndoDepartment of Advanced Medicine, University Hospital, Nagoya, Japan.
Kenichi NakamuraJCOG Data Center/Operations Office, National Cancer Center, Tokyo, Japan.
Haruhiko FukudaJapan Clinical Oncology Group (JCOG) Data Center, National Cancer Center Hospital, Tokyo, Japan.
Naomi KiyotaDepartment of Medical Oncology and Hematology, Cancer Center, Kobe University Hospital, Kobe, Japan.
PRO/QOL research Committee of Japan Clinical Oncology Group

Funding

Japan Agency for Medical Research and Development 19ck0106498h0001
6 · The paper itself

Abstract

Assessments of patient-reported outcomes and health-related quality of life in cancer clinical trials have been increasingly emphasized recently because patient and public involvement in cancer treatment development has been promoted by regulatory authorities and academic societies. To assess patient experiences during and after cancer treatment, there is interest in implementing patient-reported outcome and health-related quality of life assessments into cancer clinical trials. The Japan Clinical Oncology Group quality of life ad hoc committee previously created a version of the Quality of Life Assessment Policy in 2006. Recently, there has been increasing demand from Japan Clinical Oncology Group researchers to assess patient-reported outcome/health-related quality of life in clinical trials. Although guidelines are available regarding planning and reporting clinical trials that include patient-reported outcome/health-related quality of life as an endpoint, there are still issues regarding the lack of consensus on standardized methods for analysing and interpreting the results. Hence, it was considered necessary to reorganize the Japan Clinical Oncology Group patient-reported outcome/quality of life research committee and to revise the former patient-reported outcome/quality of life research policy to promote patient-reported outcome/health-related quality of life research in future Japan Clinical Oncology Group trials. The purpose of this Japan Clinical Oncology Group patient-reported outcome/quality of life research policy is to define patient-reported outcome/health-related quality of life research and provide guidelines for including patient-reported outcome/health-related quality of life as an endpoint in Japan Clinical Oncology Group trials.

Indexed as

NeoplasmsQuality of LifeHumansJapanMedical OncologyPolicyendpointhealth-related quality of lifeJCOGpatient-reported outcomequality of lifestudy design

Identifiers

PMID36702740
PMCPMC9991489

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.